I don't think he'd be happy even if there was mountains of pre-clinical evidence, let's be honest.
But to dismiss an entire groundbreaking arm of an FDA approved first in-human trial simply because it's not been done before, one has to wonder whether a firm grasp is held of the definitions of the words 'trial', and 'groundbreaking'. To each their own though.
Personally, and i'm not a scientist nor oncology specialist (nor is Mason, even if he has spent much time in the lab back when testing on chimps was still considered ethical) the results seen in mice where the OV traversed the body to lock onto an uninjected tumor, seem to give rise to some cause for optimism that at the right dose, IV treatment could very well prove successful.
Not investment advice. DYOR and all that
IMU Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)